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Objectives: To evaluate the association between improvements in clinical 
and patient-reported outcomes (PROs) and improvements in workplace and 
household productivity in axial spondyloarthritis (axSpA) patients treated with 
certolizumab pegol (CZP), including ankylosing spondylitis (AS) and non-radio-
graphic axSpA (nr-axSpA). MethOds: Analyses used Week (Wk) 24 data from 
the double-blind, placebo-controlled period of RAPID-axSpA (NCT01087762), for 
patients originally randomized to CZP. Responders and non-responders for clini-
cal outcomes and PROs were compared in terms of change from baseline (CFB) 
in workplace and household productivity, assessed with the arthritis-specific 
Work Productivity Survey (WPS). Groups were compared using a non-parametric 
bootstrap-t method. LOCF was used for ASDAS and WPS outcomes; NRI for ASAS40 
and PRO MCIDs. Results: 218 CZP patients entering RAPID-axSpA were ana-
lyzed at Wk24 (121 AS; 97 nr-axSpA). Patients employed at Wk24: 73.9% axSpA; 
73.6% AS; 74.2% nr-axSpA. Greater improvements in workplace productivity were 
reported by CZP-treated axSpA patients who achieved a clinical response (pres-
enteeism CFB [responders/non-responders]: -3.9/-1.0 for ASAS40; -4.3/-0.7 for 
ASDAS-MI) and reported improved physical function and less back pain (pres-
enteeism CFB [responders/non-responders]: -3.9/0.7 for BASFI MCID; -3.5/1.3 for 
total back pain MCID). Clinical responses and symptom relief were also associated 
with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -4.8/-3.6 for ASAS40; -5.1/-2.2 for BASFI 
MCID; -5.6/-0.6 for ASQoL MCID) and greater social participation (CFB in family/
social/leisure days missed [responders/non-responders]: -3.3/-1.8 for ASDAS-MI; 
-2.9/-0.8 for total back pain MCID). Nr-axSpA responders reported numerically 
greater improvements in productivity than AS responders (presenteeism CFB for 
ASDAS-MI [responders/non-responders]: -5.5/-0.5 in nr-axSpA; -3.4/-0.9 in AS). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productiv-
ity differences. cOnclusiOns: Achievement of clinical responses and symptom 
relief were associated with increased workplace and household productivity in 
CZP-treated axSpA patients, including AS and nr-axSpA.
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Objectives: Elderly patients are at higher risk for osteoporotic (OP) fractures com-
pared with the general population[1], with low-trauma fractures in elderly patients 
associated with increased mortality risk.[2] In a high proportion of patients with 
an OP fracture, OP is previously undiagnosed and no OP-medication initiated[3]. 
This market-research aimed to assess the OP-risk in geriatric patients without 
OP-diagnosis. [1] Cooper C et al. (1992): Hip fractures in the elderly: a world-wide pro-
jection. Osteoporosis international; 2(6):285-289. [2] Bliuc et al.: Mortality risk associ-
ated with low-trauma osteoporotic fracture and subsequent fracture in men and 
women. JAMA 2009 Feb 4; 301(5):513-21. [3] Klein S et al.: Osteoporose in Deutschland 
– Epidemiologie und Versorgung, 56. GMDS Jahrestagung (2011) MethOds: New 
patients to a German geriatric-practice without OP-diagnosis, completing a ques-
tionnaire (QU) with their physician evaluating OP-risk factors determined by the 
German-S3-OP-guideline[1], e.g. age, gender, BMI, were eligible. A total of 29 ques-
tions were assigned 1 or 2 points depending on OP-risk impact (total points: 0 - 31). 
A score ≥ 3 identified “OP-suspects” who were to be referred to an orthopedist. 
In orthopedic-confirmed OP-cases, OP-medication was initiated. We present 
interim data (patients completing the QU from 10/14 to 3/15). [1] http://www.dv-
osteologie.org/uploads/Leitlinie%202014/DVO-Leitlinie%20Osteoporose%202014%20
Kurzfassung%20und%20Langfassung%2018.%2009.%202014.pdf Results: Among 
53 patients included in the interim analysis, mean age was 78 years and 40 (76%) 
were post-menopausal women; 23 (43%) had co-existing diabetes and 15 (28%) 
chronic-renal-insufficiency. One-third (17 [32%]) had experienced ≥ 1 fracture after 
the age of 50. All 53 patients were identified as “OP-suspects” (mean QU-score, 
6.6 points); 29 (55%) scored ≥ 7 points indicating very high OP-risk. To date, 26 
patients had returned to the geriatric practice, with 12 (46%) having an orthopedics-
confirmed OP-diagnosis. cOnclusiOns: Our data suggest proactive evaluation 
and identification of OP is needed in the elderly population, to improve disease 
management including initiation of therapy as appropriate.
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Objectives: Osteoporosis is a chronic progressive disease characterized by low bone 
mass and deterioration of bone structure, leading to an increate risk of fractures.The 
aim of this study was to investigate the determinants of non-persistence and impact 
of persistence on the risk of fractures. MethOds: The data used for this study were 
(DLQI), and Work Productivity and Activity Impairment Index (WPAI). Patients were 
classified as achieving: full, partial, or no benefit from treatment. Full benefit was no 
PsA flare, psoriasis body surface area (BSA) = 0; a “mild” rating of physician/patient 
global perception of PsA and all skin and joint symptoms. No benefit was a PsA flare 
or physician/patient global perception of PsA that remained “moderate/severe” or 
worsened since initiation of current therapy. Everyone else achieved partial benefit. 
HRQoL was described for those with partial benefit. Residual disease was defined 
as BSA > 0%, ≥ 1 tender or swollen joint, or ≥ 1 skin or joint symptom rated as 
“moderate/severe”. Adjusted associations were estimated between residual disease, 
HRQoL, productivity and switching. Results: The sample included 398 patients; 
19.6% achieved full, 49.0% partial, and 31.4% no benefit. Of those achieving partial 
benefit, 43.1% were female, mean (SD) age 50.1 (11.8), PsA duration in months 97.9 
(91.0), BSA 8.0% (10.2%). Mean (SD) HRQoL scores for partial benefit patients were: 
0.81 (0.20) EQ-5D; 27.01, (27.10) overall work impairment; 5.17 (5.16) DLQI; 11.03 
(12.33) PROMIS HAQ; 0.35 (0.41) HAQ-DI. Residual disease was not associated with 
switching. Residual skin disease was not associated with lower EQ5D or higher 
WPAI scores. cOnclusiOns: A substantial proportion of patients yield partial or 
full benefit from biologics. In this sample, residual skin disease did not impact 
HRQoL or work productivity.
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Objectives: To estimate the willingness-to-pay (WTP) for symptom relief of tennis 
elbow and examine whether WTP is related to injury characteristics, clinical out-
comes, or other socio-demographic factors. MethOds: This cross-sectional WTP, 
contingent valuation study was performed alongside a randomised controlled trial 
comparing the addition of physiotherapy to corticosteroid injection in 165 par-
ticipants with tennis elbow. The contingent value scenario constructed required 
participants to decide the monetary value (AUD) they would pay for a quick and 
non-invasive new treatment for relief of their elbow condition. Participants were 
told to consider that their symptoms would persist for the next 12 months if left 
untreated. The efficacy of this new treatment was defined as complete recovery in 
50% of people treated. Two WTP approaches (bidding game and binary response) 
were administrated in blocks of 15 consecutive participants. For both methods, 
participants were randomly allocated a starting bid from values of $50, $650, $1250 
or $1850. Results: The bidding game approach was performed in 73 participants. 
WTP values ranged from $50 – 10000 [median WTP (IQR): $695 ($390, $940)]. WTP was 
significantly associated with an individual’s gross income, greater pain and disabil-
ity and a worsening condition. The binary response approach was performed in 87 
participants. All participants accepted a $50 bid, while more than half accepted $650 
and $1250 bids. Using this approach, participants were more likely to accept higher 
values if they had experienced greater pain and disability, a worsening condition and 
reduced pain-free grip of their affected arm. cOnclusiOns: This study examined 
the economic value that participants with tennis elbow ascribe to relief of their 
condition. The relationship between this monetary value and an individual’s injury 
characteristics and income was also demonstrated. In future work, we propose 
to compare these WTP estimates with indicators of health-related quality-of-life, 
which were also collected during this study.
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Objectives: To evaluate the association between improvements in clinical and 
patient-reported outcomes (PROs) and improvements in workplace and household 
productivity in psoriatic arthritis (PsA) patients treated with certolizumab pegol 
(CZP). MethOds: Analyses used Week (Wk) 24 data from the double-blind, placebo-
controlled period of RAPID-PsA (NCT01087788), for patients originally randomized to 
CZP. Responders and non-responders for clinical outcomes and PROs were compared 
in terms of change from baseline (CFB) in workplace and household productivity, 
assessed with the arthritis-specific Work Productivity Survey (WPS). Groups were 
compared using a non-parametric bootstrap-t method. LOCF was used for WPS out-
comes; NRI for clinical outcomes and PRO MCIDs. Results: 273 CZP patients entering 
RAPID-PsA were analyzed at Wk24. 61.9% of patients were employed at Wk24. Greater 
improvements in workplace productivity were reported by CZP-treated patients who 
achieved improved joint and skin outcomes, as well as disease remission (absentee-
ism CFB [responders/non-responders]: -1.4/-0.5 for ACR20; -1.9/-0.4 for PASI75; -1.5/-
0.6 for DAS28 remission). Clinically meaningful reductions in disability, pain and 
fatigue were also associated with increased workplace productivity (presenteeism 
CFB [responders/non-responders]: -5.4/-0.9 for HAQ-DI MCID; -3.4/-2.6 for pain MCID; 
-4.4/-0.9 for fatigue MCID). Clinical responses and symptom relief were also associ-
ated with improved household productivity (CFB in days with productivity reduced 
by ≥ 50% [responders/non-responders]: -5.8/-1.0 for ACR20; -5.5/-0.9 for PASI75; -5.1/-
3.0 for DAS28 remission; -6.0/-1.9 for HAQ-DI MCID; -5.1/-1.3 for pain MCID; -5.1/-1.7 
for fatigue MCID) and greater social participation (CFB in family/social/leisure days 
missed [responders/non-responders]: -3.0/-1.5 for PsARC; -2.9/-2.3 for fatigue MCID). 
Results should be interpreted with caution, given differences in patient number 
between groups, and because analyses were unadjusted for baseline productivity 
differences. cOnclusiOns: Achievement of disease remission, clinically meaningful 
improvements in joint and skin outcomes and symptom relief were associated with 
increased workplace and household productivity in PsA patients treated with CZP.
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Objectives: To establish the key drivers of purchasing, pricing, access, and 
profitability for biologics in markets where biosimilars, bio-originals, and new 
innovative biologics compete. To provide insight into how sustainability, profit, 
pricing and access are driven by differentiation. MethOds: A meta-analysis 
was conducted across all studies (n= 14) undertaken by GfK since January 2014 
involving the pricing and market access of biologics in Europe in inflammatory 
disease and oncology. The studies involved primary research, system dynamics 
modelling, and war gaming (competitive simulation). Primary research com-
prised interviews (n= 250) across 7 European markets: France, Germany, Hungary, 
Italy, Poland, Spain and the UK, collecting insight at pan-European, National and 
Regional levels, Physicians, Payers, Patients, and Industry. System dynamics mod-
elling, based on delphi panels of expert opinion, focused on 2 oncology products 
(trastuzumab, bevacizumab) and 3 anti-TNFs (infliximab, etanercept, adalimumab). 
War gaming was used to explore the forces of supplier and buyer power, impact 
of new entrants, impact of substitutes, and competitive rivalry. The impact of 
price referencing was included in the analysis, as was consideration of parallel 
trade. Results: The analysis showed that the key drivers of purchasing, access, 
and profitability in markets where biosimilars compete are product differentiation, 
relative effective net pricing, and multi-criteria decision-making. Both sustain-
ability and profitability are driven by differentiation. War gaming indicates that 
a market that recognizes these drivers and dynamics will deliver benefits to all 
stakeholders, including the opportunity for cost savings that can be used to fund 
access to the next generation of innovative new high cost / high value thera-
pies. cOnclusiOns: Acceptance of multi-criteria decision making that includes 
non-price criteria, a willingness to pay for differentiation, and the evolution of 
policies relating to interchangeability, substitution and switching will increase 
the stability, sustainability and profitability of markets that include biosimilars.
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Objectives: Medication persistence and adherence are important to treat-
ment success, particularly where target level achievement is critical, as in gout. 
Identifying barriers provides opportunity to improve patient outcomes. The objec-
tive is to evaluate persistence and adherence of allopurinol (ALLO) new users as 
well as relation to clinical determinants. MethOds: We assessed profile of ALLO 
use among a cohort of new ALLO users after starting an antihypertensive agents, 
using RAMQ and MED-ECHO Québec administrative databases. New ALLO users 
aged 45-85 yrs with ≥ 1 claim from Jan 1997-Jun 2007 were included. New users 
were defined as having no ALLO prescribed in the 1 yr prior to cohort entry. Cohort 
entry was defined by date of 1st ALLO claim. Adherence level was assessed by med-
ication possession ratio (MPR) and cumulative persistence rates by Kaplan-Meier 
analysis. Adjusted Cox regression models estimated rate ratio of ceasing ALLO. 
Logistic regression models established relation between non-adherence level and 
their determinants. Results: Of 2752 patients, mean age was 70 (63-76) yrs, 82% 
men. Close to 50% had ≥ 1 cardiovascular disease, dyslipidemia (33%), diabetes 
(21%), CKD (15%), and rheumatic disease (6.3%). Patients included users of low-dose 
aspirin (33%) and NSAIDs (42%). During the 1st yr, MPR was 71% and high adher-
ence (MPR ≥ 80%) was 57%. Persistence decreased to 47% after 1-yr follow-up. Non-
persistence was more likely in patients with rheumatic disease (by 25%) and in 
NSAID users (by 18%). For previous ALLO users, persistence was increased by 29%. 
Persistence was higher for intra-articular corticosteroid users (by 18%), patients 
who had had a prior use of ALLO (29%), users ≥ 7 medications (by 39%). Non-
adherence determinants were similar to those of non-persistence. cOnclusiOns: 
Barriers to persistence/adherence occur early during ALLO therapy. Adherence is 
key to determine success of many treatment approaches; greater attention may 
result in improved outcomes.
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Objectives: Biologics are drugs with a large economic burden for health care 
providers and should only be given to patients with a sever autoimmune disease 
like rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis(PS). 
The aim of this study was to evaluate the prescription reality of biologics within 
these diagnoses. MethOds: To examine the prescription reality of biologics, 
prescriptions of a large German claims data base were evaluated. Demographic, 
prescription and diagnosis data was taken from 2007 to 2013 to identify the pre-
scription routine on a yearly basis. This study included 42,441 to 92,059 patients 
per year suffering from RA, PS or AS and their observed prescriptions of biologics. 
Patients were only included if they were fully observable in the specific year of 
analysis. Results: The underlying base population of the whole claims data base 
(n = 3,6m) is fairly comparable to the overall German population regarding age, 
gender, morbidity and mortality. In 2013 84,645 AS patients, 37,839 PS and 56,570 
RA patients could be observed, where 58,45% are female (mean age = 57,55 years). 
Overall, the prescription ratio of biologics increased from 1,61% in 2007 to 3,43% in 
2013. Concerning gender, no difference in the probability of biologics prescriptions 
could be observed (57,43 % of biologics patients were female). However, a sharp 
drop in the prescription of biologics for elderly patients is present (5,8% 30-39y; 
5,5%40-59y vs 3,1% 60-69; 1,74%70-79; < 0,65% 80+). In contrast to this result, 
patients with a disease combination receive biologics more frequently (MS+AS+PS: 
29,89% vs. AS: 5,96%, PS: 2,04%, RA:9,79%). cOnclusiOns: Although the frac-
tion of patients with biologics increased in the last years, old people seem to be 
obtained from outpatient drug prescriptions, hospital discharges and ambulatory care 
records collected from January 1, 2005 to December 31, 2008. The study was designed 
as a retrospective study cohort. Patients 60 years of age or older were included if at 
least one prescription for any antiosteoporotic drugs. had been filled in between 
January 1, 2006 and December 31, 2006. For each patient, the following characteristics 
were considered:gender, age, dosing regimen, previous treatments, previous frac-
tures, co-prescription of calcium/Vitamin D, spot therapy, switcher, comorbidity. The 
primary outcome of this study was persistence at one year; the secondary outcome 
was hospitalized osteoporotic fractures based on ICD-9 codes related osteoporotic 
fracture. Results: The final cohort consisted of a total of 7,862 patients, aged > 60 
years. Kaplan – Meier analysis showed that 3,733 patients (47.5%) were persistent 
with antiosteoporotic drugs after 1 year. In the logistic regression analysis adjusted 
for potential confounders odds of fracture were significantly lower for persistent 
patients (OR:0.79). Older patients were more likely to incur a fracture than younger 
[70-79 years(OR:1.52), ≥ 80 years (OR:2.49)]. The odds of fracture were significantly 
higher for patients with previous fractures in comparison with those without previous 
fractures (OR: 1.70). cOnclusiOns: The current analysis demonstrates a significant 
association between risk of fracture and persistence. Persistence to therapy with 
antiosteoporotic drugs is important for the effectiveness of osteoporosis treatment. 
Improving osteoporosis treatment compliance and persistence is an important chal-
lenge for clinicians and the society as a whole.
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Objectives: Argentinean health system is divided in 3 subsectors: Social Security 
(48%), Public (42%) & Private (10%). It is known that the public one is the one 
with the biggest gaps in terms of capabilities, infrastructure and budget capacity 
and the most fragmented (24 differents states without standarized procedures). 
However, no local data is available regarding the accessability to biologics for the 
treatment of Rheumatoid Arthritis. The aim of the study is to describe the actual 
picture of biologics availability in the public sector, rheumatologist perception 
about main barriers and finally, to describe potential solutions. MethOds: A sur-
vey to 200 rheumatologist (Rheumatologist population in the whole country is 
witihin 400 - 600) was sent using gForms with the aim to describe the avalability of 
synthetics DMARD, biologics DMARD and targeted synthetic DMARD (Tofacitinib); 
main barriers according rheumatologist perception and budget management was 
also assessed. Results: 80% of the rheumatologist expressed that biologics are 
not avaialble in the public sector as a regular treatment, just as an “exception”. 
Among these spontaneously availability Adalimumab, Rituximab, Etanercept and 
Tocilizumab were the most named. Surprisingly, synthetic (classic) DMARD like 
metotrexate is available with severe impairements in the delivery. Main barrier 
to obtain biologics according rheumatologist perception is the restrictive budget 
allocation in the Institution, followed by biologic prices. cOnclusiOns: The pre-
sent study is the first one regarding biologic availability in the public sector in 
argentina. Big gap is seen when talking about RA treatments, moreover when a 
biologic is prescribed. Potential solutions might be: differential prices for differents 
sector, centralized drug purchasing, well design copayments, and others to be 
descripted in the poster. Full references, questionnaire with other responses and 
potential solutions are to be described in the poster.
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Objectives: Biologics are used for treatment of different diseases from cancer to 
autoimmune diseases. According to IMS biologics share in total pharma market 
in 2002 was 11% and will reach 19-20% of market share in 2017. This class of drug 
bears high costs and this is the main reason of low access to these therapies in 
developing and low income countries. Due to the costs access to this therapeutics 
depends on public funding. We examined access and trends of consumption of 
novel biologics in Bosnia and Herzegovina. MethOds: Data on consumption of 
biologics was generated from official report on annual pharmaceutical expenditure 
published by State agency for medicines and medical devices. We covered 6-years 
period (2009-2014). Access to biologics depends on public funding and has direct 
impact on expenditure and these data have been taken from official reimbursement 
lists of Health Insurance Funds financing expensive medicines. Data on expenditure 
are represented in value (EUR) and analysis did not consider volume sales. Results: 
Market share of biologics in total B&H pharma-market in 2009 was 4% and increased 
to 8% in 2014 which is highly below global trend. Monoclonal antibodies for can-
cer are present at reimbursement lists from 2009 showing constant sales growth. 
Trastuzumab is most used biologic (1,9m€ in 2009 and 6,9m€ in 2014), followed by 
rituximab, sunitinib, sorafenib and bevacizumab. Impact of reimbursementis best 
shown in case of sunitinib and sorafenib with high sales increase reflecting medi-
cal need for these therapies. Imatinib sales significantly dropped after biosimilar 
introduction into the market in 2013. Lapatinib and nilotinib had been introdudec 
into the market in 2010 and palivizumab and adalimumab in 2011 showing constant 
sales growth cOnclusiOns: Access to novel biologic depends on public funding 
and there is significant need to these therapies . Biosimilar introduction into market 
can significantly improve access to these therapies and decrease costs
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